Maria F. Pazyra-Murphy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria F. Pazyra-Murphy has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Rosalind A. Segal
Department of Neurobiology, Harvard Medical School, Boston, USA
23 shared publications - Grace H. Hwang
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts
20 shared publications - Alison Volkert
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts
19 shared publications - David A. Scott
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
19 shared publications - Georgia Dittemore
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
19 shared publications - Hyuk-Soo Seo
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, USA
19 shared publications
Latest Publications
- Open Access
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Table 4 from A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma
Supplemental Table 4 from A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 4 from A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma
Supplemental Table 4 from A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma
- Open Access
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Data from A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma
Medulloblastoma is one of the most common malignant brain tumors of children, and 30% of medulloblastomas are driven by gain-of-function genetic lesions in the Sonic Hedgehog (SHH) signaling pathway. EYA1, a haloacid dehalogenase phosphatase and transcription factor, is critical for tumorigenesis and proliferation of SHH medulloblastoma (SHH-MB). Benzarone and benzbromarone have been identified as allosteric inhibitors of EYA proteins. Using benzarone as a point of departure, we developed a panel of 35 derivatives and tested them in SHH-MB. Among these compounds, DS-1–38 functioned as an EYA antagonist and opposed SHH signaling. DS-1–38 inhibited SHH-MB growth in vitro and in vivo, showed excellent brain penetrance, and increased the lifespan of genetically engineered mice predisposed to fatal SHH-MB. These data suggest that EYA inhibitors represent promising therapies for pediatric SHH-MB.Significance:Development of a benzarone derivative that inhibits EYA1 and impedes the growth of SHH medulloblastoma provides an avenue for improving treatment of this malignant pediatric brain cancer.
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma
Medulloblastoma is one of the most common malignant brain tumors of children, and 30% of medulloblastomas are driven by gain-of-function genetic lesions in the Sonic Hedgehog (SHH) signaling pathway. EYA1, a haloacid dehalogenase phosphatase and transcription factor, is critical for tumorigenesis and proliferation of SHH medulloblastoma (SHH-MB). Benzarone and benzbromarone have been identified as allosteric inhibitors of EYA proteins. Using benzarone as a point of departure, we developed a panel of 35 derivatives and tested them in SHH-MB. Among these compounds, DS-1–38 functioned as an EYA antagonist and opposed SHH signaling. DS-1–38 inhibited SHH-MB growth in vitro and in vivo, showed excellent brain penetrance, and increased the lifespan of genetically engineered mice predisposed to fatal SHH-MB. These data suggest that EYA inhibitors represent promising therapies for pediatric SHH-MB.Significance:Development of a benzarone derivative that inhibits EYA1 and impedes the growth of SHH medulloblastoma provides an avenue for improving treatment of this malignant pediatric brain cancer.
- Open Access
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma
- Open Access
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Table 5 from A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma
Supplemental Table 5 from A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 5 from A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma
Supplemental Table 5 from A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma
- Open Access
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Table 6 from A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma
Supplemental Table 6 from A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 6 from A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma
Supplemental Table 6 from A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma
- Open Access
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Table 6 from A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma
Supplemental Table 6 from A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 6 from A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma
Supplemental Table 6 from A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma
- Open Access
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma
- Open Access
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma
Supplemental Methods and Figure Legends
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma
Supplemental Methods and Figure Legends
- Open Access
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Table 3 from A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma
Supplemental Table 3 from A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 3 from A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma
Supplemental Table 3 from A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma